CMS should look for ways to ensure that financial incentives for Medicare accountable care organizations do not promote inappropriate shifts in prescribing from the Part B benefit to Part D, biotech and clinician groups urge in comments filed with the agency June 6.

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.